H.C. Wainwright Thinks Aileron Therapeutics Inc’s Stock is Going to Recover


H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics Inc (ALRN) today and set a price target of $6. The company’s shares closed yesterday at $0.54, close to its 52-week low of $0.45.

White wrote:

“We are revising our FY19 EPS estimate to ($1.13) from ($1.08). The company reported $31.5M in cash and equivalents as of June 30, 2019. Management continues to believe the company has a cash runway into 4Q20.”

According to TipRanks.com, White is a 5-star analyst with an average return of 16.0% and a 49.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.

Aileron Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $6.

See today’s analyst top recommended stocks >>

Based on Aileron Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.21 million. In comparison, last year the company had a GAAP net loss of $9.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts